RE:RE:RE:RE:3 New Contracts and Share Price DownStill trade at 8 times expected 2021 revenue, far to be insignificant, when DOC a real success story around 3 based on $140 annualized run rate.
Outside WSR poorly efficient and costly pumping machine, no real analyst follow the stock as in 2017.